오소바이오로직스 시장 : 규모, 점유율, 동향 분석, 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Orthobiologics Market Growth & Trends:

The global orthobiologics market size is estimated to reach USD 10.34 billion by 2033, expanding at a CAGR of 4.74% from 2025 to 2033, according to a new report by Grand View Research, Inc. Increasing cases of orthopedic surgeries across the globe is driving the demand for orthobiologics. A study presented at the Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) 2023, revealed that orthopedic surgeons would face a challenge in meeting the increasing demand for total joint arthroplasty (TJA). The study found that to keep up with the demand, surgeons will have to either double their TJA caseload or increase the number of surgeons by 10% every five years.

With an increasing focus on healthcare advancements and patient outcomes, governments worldwide are implementing policies and initiatives to foster the growth of orthobiologics. For instance, the American Academy of Orthopedic Surgeons (AAOS) is committed to improving musculoskeletal care in a transparent and scientific way. In October 2020, the AAOS launched the Biologics Dashboard on their website, which is designed to assist orthopedic surgeons in keeping track of the approval status of biologic-based interventions. This initiative is a part of the AAOS Biologics Initiative, which offers evidence-based guidance to the musculoskeletal health community. As part of this effort, the AAOS Board of Directors also revised two position statements related to biologics.

Increasing geriatric population across the globe is also anticipated to boost the demand for orthopedic surgeries. According to the India Ageing Report 2023, country's elderly population is growing at a rapid pace, with a decadal growth rate of 41%. By 2050, over 20% of India's population will be elderly citizens.As people age, they are more likely to experience issues with their muscles and bones, such as osteoporosis, osteoarthritis, and fractures. This results in a greater need for orthobiologics solutions.

Moreover, increasing cases of road accidents is anticipated to supplement the market growth. According to the National Highway Traffic Safety Administration report, there were an estimated 19,515 deaths in motor vehicle accidents during the first half of 2023. This represents a decrease of about 3.3% compared to the same period in the previous year, which had 20,190 fatalities. The report also shows that fatalities decreased during both the first and second quarters of 2023. Thus, the increasing number of injured populations is expected to increase the demand for orthobiologics.

The major players operating in the market are adopting strategies such as collaborations, supply agreements, and partnerships with a major focus on enhancing the product formation and reach. For instance, inSeptember 2023, HippoFi Inc. partnered with Zimmer Biomet Holdings Inc. to bring forth a synthetic biomaterial for bone growth. The biomaterial will be launched under HippoFi's biologic subsidiary, PUR Biologics in 2024.

Orthobiologics Market Report Highlights:

• Based on product, the viscosupplementation segment dominated the orthobiologics market in 2024 and accounted for the largest revenue share of 42.21% owing to the increasing prevalence of lifestyle-related conditions and advances in hyaluronic acid therapy development
• Based on application, the spinal fusion segment held the largest revenue share of over 48.29% in 2024 owing to the rising incidence of degenerative disc disease
• Based on end-use, the hospitals segment dominated the orthobiologics industry in 2024 with a revenue share of over 75% due to the growing patient population undergoing surgical procedures
• North America dominated the orthobiologics market in 2024 and accounted for the largest revenue share of 46.03%

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment scope
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Orthobiologics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing number of sports injuries and road traffic accidents
    • 3.2.1.2. Increasing adoption of minimally invasive treatments
    • 3.2.1.3. Increasing reimbursement coverage for orthopedic procedures
    • 3.2.1.4. Growing aging population and increase in chronic diseases
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Availability of alternative treatments
    • 3.2.2.2. Stringent regulatory framework
• 3.3. Orthobiologics: Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTLE Analysis
• 3.4. Regulatory Framework
• 3.5. Orthopedic Disease Prevalence
  • 3.5.1. North America
  • 3.5.2. Europe
  • 3.5.3. Asia Pacific
  • 3.5.4. Latin America
  • 3.5.5. Middle East and Africa
• 3.6. Initiatives by key stakeholders in the Orthopedic Industry
• 3.7. Orthopedic Industry Funding Market
  • 3.7.1. 10 Orthopedic Companies Close New Funding Rounds in 1Q24 Funding
  • 3.7.2. Funding Announcements

Chapter 4. Orthobiologics Market Segment Analysis, By Product, 2021-2033 (USD Million)

• 4.1. Definition and Scope
• 4.2. Product Type Market Share Analysis, 2021 & 2033
• 4.3. Segment Dashboard
• 4.4. Global Orthobiologics Market, by Product Type, 2021 to 2033
• 4.5. Demineralized Bone Matrix (DBM)
  • 4.5.1. Demineralized Bone Matrix (DBM) market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.6. Allograft
  • 4.6.1. Allograft market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.7. Bone morphogenetic protein (BMP)
  • 4.7.1. Bone morphogenetic protein (BMP) market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.8. Viscosupplementation
  • 4.8.1. Viscosupplementation market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.9. Synthetic bone substitutes
  • 4.9.1. Synthetic bone substitutes market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.10. Stem cell therapy
  • 4.10.1. Stem cell therapy market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Orthobiologics Market Segment Analysis, By Application, 2021-2033 (USD Million)

• 5.1. Definition and Scope
• 5.2. Application Market Share Analysis, 2021 & 2033
• 5.3. Segment Dashboard
• 5.4. Global orthobiologics Market, by Application, 2021 to 2033
• 5.5. Spinal Fusion
  • 5.5.1. Spinal fusion market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.6. Trauma repair
  • 5.6.1. Trauma repair market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.7. Reconstructive surgery
  • 5.7.1. Reconstructive surgery market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Orthobiologics Market Segment Analysis, By End Use, 2021-2033 (USD Million)

• 6.1. Definition and Scope
• 6.2. End Use Market Share Analysis, 2021 & 2033
• 6.3. Segment Dashboard
• 6.4. Global Orthobiologics Market, by end use, 2021 to 2033
• 6.5. Hospitals
  • 6.5.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.6. Orthopedic Clinics
  • 6.6.1. Orthopedic Clinics market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Orthobiologics Market Segment Analysis, By Region, By Product, By Application, By End Use, 2021- 2033 (USD Million)

• 7.1. Regional Market Share Analysis, 2021 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Regional Market Snapshot
• 7.4. Orthobiologics Market Share by Region, 2021 & 2033:
• 7.5. North America
  • 7.5.1. North America orthobiologics market, 2021 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. U.S. orthobiologics market, 2021 - 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Canada orthobiologics market, 2021 - 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe orthobiologics market, 2021 - 2033 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. UK orthobiologics market, 2021 - 2033 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Germany orthobiologics market, 2021 - 2033 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. France orthobiologics market, 2021 - 2033 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Italy orthobiologics market, 2021 - 2033 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Spain orthobiologics market, 2021 - 2033 (USD Million)
  • 7.6.7. Norway
    • 7.6.7.1. Norway orthobiologics market, 2021 - 2033 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Sweden orthobiologics market, 2021 - 2033 (USD Million)
  • 7.6.9. Denmark
    • 7.6.9.1. Denmark orthobiologics market, 2021 - 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Japan orthobiologics market, 2021 - 2033 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. China orthobiologics market, 2021 - 2033 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. India orthobiologics market, 2021 - 2033 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Australia orthobiologics market, 2021 - 2033 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. South Korea orthobiologics market, 2021 - 2033 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Thailand orthobiologics market, 2021 - 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Brazil orthobiologics market, 2021 - 2033 (USD Million)
  • 7.8.2. Mexico
    • 7.8.2.1. Mexico orthobiologics market, 2021 - 2033 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Argentina orthobiologics market, 2021 - 2033 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. South Africa orthobiologics market, 2021 - 2033 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Saudi Arabia orthobiologics market, 2021 - 2033 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. UAE orthobiologics market, 2021 - 2033 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Kuwait orthobiologics market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Profiles
  • 8.3.1. Medtronic Plc
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Product benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. DePuy Synthes
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Zimmer Biomet
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Stryker Corporation
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Bioventus LLC
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Seaspine Holdings Corporation
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Orthofix, Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Globus Medical
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Arthrex, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Bone Biologics Corp.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives